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Summary
Objective: To investigate the differences in gene expression proﬁles of adult articular cartilage with endemic osteoarthritis (OA), KashineBeck
disease (KBD), and the same regions in the normal joint.
Methods: The messenger RNA expression proﬁles of articular cartilage with KBD diagnosed according to ‘‘Diagnosing Criteria of Kashine
Beck Disease in China’’ were compared with the normal cartilage. Total RNA isolated separately from four pairs of the KBD and normal
cartilage samples were evaluated by oligonucleotide microarray analysis. The microarray data were conﬁrmed by quantitative real-time
reverse transcription polymerase chain reaction (qRT-PCR) ampliﬁcation and were compared with previously published experiments.
Results: About 4100 transcripts, which corresponded to 35% of the expressed transcripts, showed twofold differences in expression
between the cartilage tissues in pairs. Approximately 2% of the expressed genes (79, 55 genes expressed in KBD> normal; 24 genes
expressed in KBD< normal) were commonly expressed in the four pairs of samples. The expression of some genes related to the metabolism,
apoptosis, cell proliferation and matrix degradation activity was signiﬁcantly different in KBD cartilage than in the normal, similar to the ﬁndings
for genes that inhibit matrix degradation. Comparisons of qRT-PCR data and the previously reported data with the result of gene chips support
the validity of our microarray data.
Conclusion: Differences between KBD cartilage and the normal exhibited a similar pattern among the four pairs examined, indicating the pres-
ence of common mechanisms mainly including chondrocyte metabolism and apoptosis that contribute to cartilage destruction in KBD.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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KashineBeck disease (KBD) is an endemic osteochondrop-
athy inChina and other parts of Asia, affecting over 0.74million
patients with 10.342 million people at risk1,2. To date no
consensus has been reached on the etiology, although three
major environmental hypotheses have been proposed in the
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83contamination by mycotoxin-producing fungi, and high humic
acid levels in drinking water3e7.
Previously, the histological and morphological changes,
differing from those observed in osteoarthritic cartilage,
have been seen in the articular cartilage of KBD, including
signiﬁcant alterations in chondrocyte phenotype, chondro-
cyte necrosis and apoptosis, and abnormal terminal chon-
drocyte differentiation8e10. KBD is considered to be
a heterogeneous group of disorders with a variety of patho-
genic factors, all of which result in similar patterns of carti-
lage degeneration and articular deformation11. The
pathological changes in KBD articular cartilage include sur-
face ﬁbrillation, chondrocyte clustering, collagen II degrada-
tion and loss of proteoglycans from the matrix following
a focal chondrocyte necrosis in deep zone. A correlation
to chondronecrosis cartilage samples from children and
adults with KBD has been reported8,12. It is an urgent
need to better understand its pathogenesis to enable the
development of new management and treatment strategies.
84 W. Z. Wang et al.: Gene expression proﬁle of KBD cartilageArticular cartilage, which is an avascular deformable
tissue including chondrocytes and the extracellular matrix
(ECM) produced by them, plays a critical role in degenera-
tion and deform of joints in KBD. To unravel the pathogenic
mechanisms of KBD, the analysis of mRNA expression
relevant to KBD can provide valuable insight into the phys-
iopathological events or intracellular pathways involved with
the disease.
Comprehensive mRNAs’ expression proﬁles of human
cartilage in KBD and the normal have never been
compared, thus, the following questions remain unresolved.
What percentageof the expressed transcripts showsobvious
differences in expression levels in cartilage between KBD
and the normal? Which transcripts show differential expres-
sion pattern in articular cartilage with KBD?What are themo-
lecular functions involved in such groups of genes?
To provide answers to these questions, Agilent Human
1A 22 k high-density oligonucleotide array analysis was
used to compare the gene expression proﬁle of chondro-
cytes in KBD articular cartilage with the one in the normal
cells. The validity of oligonucleotide array data was evalu-
ated on the basis of the parallel analyses of quantitative
real-time reverse transcription polymerase chain reaction
(qRT-PCR) ampliﬁcation.Materials and methodsCARTILAGE SAMPLESSpecimens of human articular cartilage were collected from a total of 15
KBD patients and nine normal. In order to match the age and sex, selected
nine samples of the 15 patients’ samples were used for microarray analysis
and qRT-PCR analysis after histologic assessment (Table I). Patients were
undergoing total knee replacement surgery at the hospital (three females/
six males aged from 42 to 69 years old). KBD adults selected were
diagnosed as the second and third degree, based on the Diagnosing Criteria
of KashineBeck Disease in China13 by radiography of the right hand, knee
and hip joints and cartilage sections after hematoxylin and eosin (H&E) stain-
ing. The normal control group, which consisted of nine human articular
cartilage samples (three females/six males aged from 34 to 60 years old),
was collected from the fresh cadaver knees within 8 h of death, donated
with a fairly large amount of cartilage from the same anatomical site as in
KBD group. The cadaver donors, who died in trafﬁc accidents, were from
non-KBD areas and excluded KBD, and status of control cartilage samples
was diagnosed by histological examination with H&E staining, and excluded
the genetic bone and cartilage diseases, OA, and rheumatoid arthritis.
Cartilage tissue on condyles of femur was dissected and rapidly frozen in
liquid nitrogen and stored at 80 C until RNA isolation was performed.
This investigation was approved by the Human Ethics Committee, Xi’an
Jiaotong University. All patients or relatives of donors provided an informed
consent.Table I
Normal/KBD sample pairs used for microarray and qRT-PCR
analysis
Normal KBD
Set 1 54 y (M) 52 y (M)
55 y (M) 55 y (M)
48 y (F) 49 y (F)
37 y (M) 42 y (M)
Set 2 60 y (M) 69 y (M)
58 y (M) 51 y (M)
56 y (M) 50 y (M)
58 y (F) 57 y (F)
34 y (F) 44 y (F)
Set 1: microarray analysis and set 2: real-time quantitative PCR
analysis. KBD e KashineBeck disease, F e female, and
M e male.RNA EXTRACTION, NORMALIZATION OF THE AMOUNT
OF RNA AND MICROARRAY ANALYSISSamples from the KBD or the control group were divided into four pairs
and underwent microarray analysis (Table I). In brief, frozen cartilage tissue
of each sample was rapidly ground in liquid nitrogen with freezer mill (SPEX
CertiPrep, Metuchen, NJ, USA)14. Total RNA was isolated separately using
the Agilent total RNA isolation minikit (Agilent Technologies, Santa Clara,
CA, USA) according to the manufacturer’s protocol. The Human-Actin
Competitive PCR Set (Takara Bio, Kyoto, Japan) was used according to
the manufacturer’s instructions to normalize the RNA amount that would
be available for microarray analysis. To conﬁrm the integrity of the total
RNA, 60 ng (normalized value) of denatured total RNA was loaded in each
lane of a 1% non-denaturing (formaldehyde-free) agarose gel, subjected to
electrophoresis, and stained with ethidium bromide. Smaller amounts of total
RNA can be detected in non-denaturing agarose gels than in formaldehyde-
denaturing agarose gels. It was further transcribed in vitro into cRNA and
labeled with CyDye using Amino Allyl MessageAmp aRNA Kit (Ambion)
according to the manufacturer’s protocol. Then, 0.5 mg of each labeled
cRNA of reference and experimental sample were puriﬁed, combined, and
mixed with hybridization buffer before being applied on the microarray. The
hybridization solution was prepared using in situ hybridization kit plus
(Agilent Technologies). The ﬂuorescent labeled cRNA was used for oligo
microarray hybridization. Hybridizations of each pair were carried out using
Agilent Human 1A 22 k oligo microarray (Agilent Technologies, G4110B)
containing 22,575 oligonucleotides that represent more than 20,173 human
genes. Hybridization was performed in the hybridization chamber (Gene-
Machines, San Carlos, CA, USA). Conditions of hybridization and washing
were according to the protocol of Agilent Oligonucleotide Microarray Hybrid-
ization (Agilent Technologies).ANALYSIS OF THE DATAThe quality of the ﬂuorescence spots of the microarray data was evalu-
ated as ‘‘present’’ or ‘‘absent’’ and selected through automatic recognition.
The data were recorded and transferred into text ﬁles using Feature Extrac-
tion 9.3 Software (Agilent Technologies) and Spotﬁre 8.0 (Spotﬁre Inc.,
Cambridge, MA, USA). The spots that failed to pass quality control proce-
dures of these softwares were ﬂagged and excluded from further analysis.
A possible dye bias was eliminated using an algorithm for the same extrac-
tion software (Extraction 9.3 Software, Agilent) that applies normalization
factors (global normalization, location normalization). Generated ﬁles were
imported into spreadsheets (Excel, Microsoft Corp., Redmond, WA, USA)
for downstream data analysis and statistical evaluation. The more detailed
process can be accessed from the Agilent Company. Then, individual genes
were classiﬁed as ‘‘up-regulation’’ or ‘‘down-regulation’’ when the fold
change of spot labeling intensity was more than twofold or less than 0.5-
fold in pairs, respectively. The ‘‘fold change’’ value represents the ratio of
the individual signal intensity in KBD to the individual signal intensity in the
normal of all four pair samples.
To identify the genes that showed the same expression pattern in different
groups, the selection criteria were deﬁned so that selected transcripts had to
show a more than twofold difference in the level of expression among all four
pair samples (Fig. 1). The standard error of the mean (S.E.M.) was calculated
from the standard deviation (SD) of the fold change value.qRT-PCRTotal RNA was prepared in the same way as for the oligonucleotide array
analysis. These RNA samples were converted into cDNA using Superscript
II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) and random primer.
qRT-PCRs were performed using the ABI7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s
instructions. Primer and probe sets were purchased as TaqMan Gene
Expression Assays for the set of genes to be analyzed: NM_001236
(CBR3), NM_006475 (POSTN ), NM_001003940 (BMF ), NM_006283
(TACC1), NM_003376 (VEGF ), NM_021992 (TMSL8), NM_012115 (CAS-
P8AP2), NM_001015880 (PAPSS2). Results were normalized to the expres-
sion of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The fold
change was calculated as described above.ResultsFINDINGS OF THE GENOME-WIDE SCREENINGThe Agilent Human 1A high-density oligonucleotide array
system was used to compare gene expression proﬁles of
chondrocytes in KBD joint cartilage with the proﬁle of chon-
drocytes in normal joint cartilage. There are 22,575 probe
Fig. 1. Flow chart showing the procedure for identifying genes with different expression levels in human cartilage of KBD and the normal. The
terms ‘‘present,’’ and ‘‘absent’’ represent expression levels of the transcripts described in Materials and methods. Values are the meanSD
number and percentage of transcripts. See Materials and methods for details of the selection criteria.
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probes, 162 negative control probes and 422 ignore probes,
covering more than 18,000 transcripts variants that repre-
sent 21,073 human genes. The expression analysis
detected 55% (meanSD 11,928 1134) of all probe
sets corresponding to the transcripts in each cartilage sam-
ple (Fig. 1). However, little difference was noted between
the percentage of transcripts expressed in KBD and the
normal tissues: KBD 53.9 4.6% (12,158 1038) vs
normal 51.8 8.1% (11,697 1830). More than twofold
difference in expression per sample was noticed in
18.2 3.5% (4101 793) of all probe sets: expression
was higher in KBD samples in 9.4 3.2% (2121 716) of
the transcripts, and lower in 8.8 3.7% (1980 842) of
the transcripts. This corresponds to 35% of the expressed
transcripts (4101/11,928¼ 0.344). Furthermore, 2% of
differentially expressed genes were commonly detected in
all four pairs (79/4101¼ 0.019).
Thus, we identiﬁed 79 genes, which consisted of 55
genes expressed at higher and 24 genes expressed at
lower level in KBD than in normal cartilage. These genes
were then subdivided into functional categories: the genes
with higher expression in KBD group were subdivided into
12 categories, including metabolism, ECM, secreted inhibi-
tors/antagonists, transcription regulator/factors, G protein
correlated, acceptor, DNA modiﬁcation, cytokines/growth
factors, proteases, oncogene correlated, signal transduc-
tion and miscellaneous, and the genes with higher expres-
sion in normal group into 14 categories, including DNA
modiﬁcation, signal transduction, transcription correlated,
oncogene correlated, cytokines/growth factors, ECM, devel-
opment correlated, apoptosis, cell cycle, membrane
proteins/receptor, cytoskeleton and cell movement, metab-
olism and miscellaneous. Data for all of the selected genes
are shown in Tables II and III.RESULTS OF REAL-TIME QUANTITATIVE
PCR OF SELECTED EIGHT GENESTo validate the oligonucleotide array data, qRT-PCR was
performed on eight selected genes using additional ﬁvepairs of cartilage samples. For these eight genes, the
groups of high expression as determined by qRT-PCR
were consistent with the groups of high expression as
determined by oligonucleotide array analysis. We found
that the levels of mRNA expression for POSTN, CBR3,
BMF, TACC1, VEGF, TMSL8, CASP8AP2 and PAPSS2
genes in KBD and the normal were signiﬁcantly different
as determined by qRT-PCR methods (Fig. 2), and more
importantly, the changes were rather consistent with the
array data.EXPRESSION PATTERNS OF GENES REPORTED
TO BE DIFFERENTIALLY EXPRESSED IN KBD,
AND IN OA VS THE NORMAL CARTILAGEThe expression level of some of the genes that, on the
basis of the present microarray data or shown in the previ-
ous studies, were differentially expressed in KBD cartilage
vs the normal were further assessed. We conﬁrmed
elevated gene expression of Bcl-2, Bax, vascular endothe-
lial growth factor (VEGF), Col5 and Col1 in KBD articular
cartilage. Our list of differentially expressed genes was
compared with a previously published list of differences
between intact-looking vs damaged OA cartilage15. We
could identify 11 up-regulated and three down-regulated
genes behaving similarly both in KBD and OA. The names
and symbols of these genes are shown in Table IV. Despite
the presence of similarly behaving genes, there were still
a number of differentially expressed genes that were
speciﬁc for KBD.Discussion
Despite considerable limitations such as low sensitivity and
insensitivity to alternative splicing, posttranscriptional regula-
tion, and posttranslational modiﬁcation, cDNA array technol-
ogy provides a powerful tool, which we can exploit to obtain
an overview of gene expression patterns, hardly achievable
with other techniques. This has been shown to be true for the
analysis of knowngenes aswell as the discovery of newgenes
Table II
List of genes with lower expression in KBD than normal cartilage in microarray data
Category Gene name Public ID Gene symbol Fold change S.E.M.
Metabolism Cathepsin K NM_000396 CTSK 0.47 0.12
Carbonyl reductase 3 NM_001236 CBR3 0.36 0.09
Homeodomain interacting protein kinase 2 NM_022740 HIPK2 0.32 0.08
Fatty acid binding protein 4, adipocyte W60781 FABP4 0.38 0.09
HtrA serine peptidase 3 NM_053044 HTRA3 0.38 0.08
ECM Fibulin-1 NM_006486 FBLN1 0.14 0.06
Tenascin XB NM_019105 TNXB 0.36 0.13
Secreted inhibitors/antagonists BMP-binding endothelial regulator precursor protein NM_133468 BMPER 0.33 0.14
Transcription regulator/factors Transforming, acidic coiled-coil containing protein 1 NM_006283 TACC1 0.43 0.03
Homeo box C10 NM_017409 HOXC10 0.42 0.04
Homo sapiens checkpoint suppressor 1 NM_005197 CHES1 0.28 0.10
G protein correlated Regulator of G protein signaling 10 NM_001005339 RGS10 0.43 0.05
Frizzled homolog 8 (Drosophila) NM_031866 FZD8 0.41 0.10
Acceptor Retinal outer segment membrane protein 1 NM_000327 ROM1 0.34 0.10
DNA modiﬁcation Zinc ﬁnger with KRAB and SCAN domains 1 AY260738 ZKSCAN1 0.40 0.08
Cytokines/growth factors Periostin, osteoblast speciﬁc factor NM_006475 POSTN 0.27 0.12
Synaptopodin 2-like NM_024875 SYNPO2L 0.32 0.11
Cathepsin C NM_001814 CTSC 0.29 0.12
Development correlated Aortic preferentially expressed gene 1 NM_005876 APEG1 0.40 0.08
Oncogene correlated Bcl2 modifying factor NM_001003940 BMF 0.37 0.09
RAS, dexamethasone-induced 1 NM_016084 RASD1 0.41 0.03
Miscellaneous Regulator of G protein signaling 5 NM_003617 RGS5 0.27 0.14
Chromosome 11 open reading frame 8 NM_001584 C11orf8 0.39 0.07
Unknown A_23_P142113 A_23_P142113 0.39 0.04
See Materials and methods for the deﬁnition of the selection criteria and for the method of calculating the ‘‘fold change’’ and the S.E.M. Public
ID¼ accession number in public databases (RefSeq or GenBank).
86 W. Z. Wang et al.: Gene expression proﬁle of KBD cartilageof interest. It is increasingly being used to investigate the basis
of disease, leading to the generation of gene proﬁles for
disease screening and gene targets for drug therapy16,17.
In this study, we compared the gene expression proﬁles in
KBD cartilage vs the normal one using oligonucleotidemicro-
array. Transcripts with a twofold difference in mRNA expres-
sion between these two samples accounted for an average of
34% of all expressed transcripts per pairs of cartilage tissue
sample, 2% of which were commonly detected in the four
sample pairs. The former observations have indicated that
some gene expressions of chondrocytes in KBD cartilage
were quite different from those of chondrocytes in the normal
tissue, even though both paired sample groups were
harvested from the same anatomic regions and the patients
at similar ages. This ﬁnding suggests that the gene expres-
sion proﬁles of chondrocytes in KBD cartilage changes in
a speciﬁc manner. Thus, there may be a common molecular
mechanismofKBDdevelopment, assuming that the changes
in gene expression patterns of chondrocytes lead to cartilage
deformity. However, based on gene array data alone it is
difﬁcult to evaluate, which of changes observed derive from
primary processes of KBD and which result from secondary
responses due to cartilage degeneration.
Using our selection criteria, we identiﬁed 79 genes that
were differentially expressed in KBD vs the normal cartilage.
The validity of our datawas conﬁrmedusing qRT-PCRandby
comparing our present ﬁndings with those of the previous
studies. The possible roles of these genes with signiﬁcantly
altered mRNA expression are discussed here in order to
reveal possible clues of the underlying mechanisms that
may participate in the pathogenesis or progression of KBD,
such as chondrocyte metabolism, ECM, proliferation and
apoptosis activity of chondrocytes.
With regard to chondrocyte metabolism, ERH, PAPSS2,
GSTT2, FABP4, CTSC, HIPK2, HTRA3, PDE4B, PDK3,
IDH2, PDE8B, etc., genes were found to be differentiallyexpressed between KBD and the normal human cartilage.
Sulfation of proteoglycans is a very important posttransla-
tional modiﬁcation in chondrocyte growth and development.
The enzyme 30-phosphoadenosine 50-phosphosulfate syn-
thase (PAPSS) catalyzes the biosynthesis of PAPS (30-
phosphoadenosine 50-phosphosulfate), which serves as
the universal sulfate donor compound for all sulfotransfer-
ase reactions18. Mutations of PAPSS2 gene in the murine
and human are responsible for diseases affecting the skel-
etal system and play an important role of the gene product
for cartilage growth and development in mouse embryo19.
Overexpression of PAPSS could lead to higher activity of
PAPS, which might cause higher sulfation of cartilage pro-
teoglycans. However, it is difﬁcult to evaluate its role in
KBD, since it is not clear whether the sulfation degree of
KBD cartilage differs from normal.
GlutathioneS-transferase theta 2 (GSTT2) belongs toa fam-
ily of detoxiﬁcation enzymes, and its overexpression is thought
to provide the cells with protection against oxidative stress and
various drugs20. The fact that serious cereal contamination by
T-2 toxin, moniliformin and butenolide (BUT) and high humic
acid levels in drinking water have been found in KBD
areas5,12,21 suggests that the pathogenetic mechanisms in
chondrocytes of KBD might be related to poison. It has also
been reported that low selenium level may cause oxidative
DNA base damage in KBD3,22e24. Previous data have
suggested that enhancer of rudimentary homolog (ERH)might
be an important transcription regulator that also functions in the
control of cell-cycle progression25. Fatty acid binding proteins
(FABPs) are proteins that reversibly bind fatty acids and other
lipids. So far, nine tissue-speciﬁc cytoplasmic FABPs have
been identiﬁed. Adipose tissue FABP (FABP4) has been
suggested as a bridge between inﬂammation and other path-
ways related to the metabolic syndrome26. Adipocyte fatty
acid binding protein, aP2 (FABP4) is expressed in adipocytes
andmacrophages, and integrates inﬂammatory andmetabolic
Table III
List of genes with higher expression in KBD than normal cartilage in microarray data
Category Gene name Public ID Gene symbol Fold change S.E.M.
DNA modiﬁcation Heme binding protein 2 NM_014320 HEBP2 2.67 0.49
ADP-ribosylation factor-like 7 NM_005737 ARL4C 5.07 3.61
Signal transduction ABI gene family, member 3 (NESH) binding protein NM_015429 ABI3BP 2.83 0.66
Transcription correlated LIM and cysteine-rich domains 1 NM_014583 LMCD1 4.27 1.66
Goosecoid NM_173849 GSC 3.33 0.92
Homeo box B2 NM_002145 HOXB2 5.08 2.28
Oncogene correlated B-cell translocation gene 1, anti-proliferative NM_001731 BTG1 8.48 6.20
Cytokines/growth factor Insulin-like growth factor binding protein 4 NM_001552 IGFBP4 4.13 1.53
IGF-II mRNA-binding protein 2 NM_000597 IGFBP2 9.70 3.73
Transforming growth factor, beta-induced, 68 kDa NM_000358 TGFBI 7.86 3.44
LIM domain only 4 NM_006769 LMO4 2.69 0.35
Scrapie responsive protein 1 NM_007281 SCRG1 2.55 0.32
Chordin-like 2 NM_015424 CHRDL2 3.60 0.58
Vascular endothelial growth factor NM_003376 VEGF 2.99 0.52
ECM Collagen, type V, alpha 2 NM_000393 COL5A2 8.85 6.83
Collagen, type I, alpha 1 NM_000088 COL1A1 4.92 1.80
Thrombospondin 1 NM_003246 THBS1 2.95 0.76
Hyaluronan and proteoglycan link protein 1 NM_001884 HAPLN1 7.50 4.70
Procollagen-proline, 2-oxoglutarate 4-dioxygenase
(proline 4-hydroxylase), alpha polypeptide III
NM_182904 P4HA3 3.42 1.40
Development correlated Brain expressed, X-linked 1 NM_018476 BEX1 4.99 1.19
Likely ortholog of mouse limb-bud and heart gene NM_030915 LBH 3.31 1.39
Eyes absent homolog 2 (Drosophila) NM_172113 EYA2 2.87 0.28
Apoptosis Growth-arrest-speciﬁc 2-like 1 NM_152236 GAS2L1 7.63 3.76
Tumor necrosis factor, alpha-induced protein 6 NM_007115 TNFAIP6 5.94 1.52
Death-associated protein kinase 1 NM_004938 DAPK1 3.09 0.98
Tumor necrosis factor receptor superfamily,
member 11b (osteoprotegerin)
NM_002546 TNFRSF11B 8.53 8.01
BCL2-antagonist/killer 1 NM_001188 BAK1 5.97 1.57
B-cell CLL/lymphoma NM_004324.2 BCL2 3.23 0.97
PERP, p53 apoptosis effector NM_022121 PERP 5.59 2.38
CASP8 associated protein 2 NM_012115 CASP8AP2 5.43 3.64
Apoptotic protease activating factor NM_181861 APAF1 5.70 3.92
Homo sapiens caspase 6, apoptosis-related cysteine
peptidase, transcript variant alpha, mRNA
NM_001226 CASP6 8.33 5.50
BCL2-associated X protein NM_004324.2 BAX 3.79 1.53
Tumor necrosis factor (ligand) superfamily member 14 NM_003807 TNFSF14 2.72 0.58
Cell cycle CDC37 cell division cycle 37 homolog NM_007065 CDC37 2.67 0.37
Membrane proteins/
receptor
Frizzled homolog 1 (Drosophila) NM_003505 FZD1 3.67 1.25
Frizzled homolog 10 (Drosophila) NM_007197 FZD10 2.49 0.18
Cystoskeleton and
cell movement
Thymosin-like 8 NM_007059 TMSL8 9.65 8.50
Tubulin, beta 2 NM_001069 TUBB2A 3.27 0.70
Stathmin-like 2 NM_007029 STMN2 11.17 3.84
Metabolism PAPSS2 NM_001015880 PAPSS2 3.79 1.21
Phosphodiesterase 4B, cAMP-speciﬁc
(phosphodiesterase
E4 dunce homolog, Drosophila)
NM_001037341 PDE4B 3.38 1.27
Isocitrate dehydrogenase 2 (NADPþ), mitochondrial NM_002168 IDH2 4.31 0.71
Phosphodiesterase 8B NM_003719 PDE8B 8.47 4.08
Pyruvate dehydrogenase kinase, isoenzyme 3 NM_005391 PDK3 3.00 0.67
UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 1 (GalNAc-T1)
XM_031104 GALNTL1 8.16 2.62
Glutathione S-transferase theta 2 NM_000854 GSTT2 4.01 1.51
Enhancer of rudimentary homolog
(Drosophila)
NM_004450 ERH 7.50 2.12
Miscellaneous Serine (or cysteine) proteinase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1), member 1
A_23_P123234 A_23_P123234 5.70 2.27
FAT tumor suppressor homolog 4 (Drosophila) AK026709 FAT4 3.53 0.25
Suppressor of cytokine signaling 3 NM_003955 SOCS3 3.01 0.71
Gremlin 1 homolog, cysteine knot superfamily
Xenopus laevis)
NM_013372 GREM1 6.79 4.81
Fer-1-like 3, myoferlin NM_013451 FER1L3 2.82 0.61
Nipsnap homolog 3A NM_015469 NIPSNAP3A 2.97 0.61
Vestigial-like 3 NM_016206 VGLL3 4.10 1.83
See Materials and methods for the deﬁnition of the selection criteria and for the method of calculating the ‘‘fold change’’ and the S.E.M. Public
ID¼ accession number in public databases (RefSeq or GenBank).
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Fig. 2. Histogram showing levels of expression of eight selected
genes, as measured by oligonucleotide array (solid bars: n ¼ 4)
and real-time quantitative polymerase chain reaction (open bars:
n¼ 5).Values are the meanSD (see Materials and methods for
further details).*P< 0.05, yP> 0.01 for KBD vs the normal, by
paired t-test.
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possible, and may lead to a new class of powerful therapeutic
agents to prevent and treat metabolic diseases27.
Cathepsin C (CTSC), member of the papain family of
cysteine proteinases, is a lysosomal aminopeptidase.
Cathepsins are synthesized in the endoplasmic reticulum
as pre-proproteins consisting of a signal peptide, a propep-
tide and a catalytic region of the enzyme. In addition to the
intracellular degradation of collagens, cathepsins can also
degrade matrix proteins extracellularly28. Homeodomain
interacting protein kinase 2 (HIPK2) is an evolutionary
conserved serine/threonine kinase that regulates gene
expression by phosphorylation of transcription factors and
accessory components of the transcription machinery.
HIPK2 is activated in response to DNA-damaging agents
or morphogenic signals and accordingly HIPK2-guidedTable I
List of genes behaving similarly both in the present KBD microarray data, a
cartilage
Comparison,
expression
Gene symbol Gene name
Intact<
damaged
ABI3BP ABI gene family, member 3 (NESH
binding protein
COL1A1 Collagen, type I, alpha 1
COL5A1 Collagen, type V, alpha 1
FZD1 Frizzled homolog 1 (Drosophila)
FZD10 Frizzled homolog 10 (Drosophila)
GALNTL1 UDP-N-acetyl-alpha-D-galactosami
polypeptide N-acetylgalactosaminy
TGFBI Transforming growth factor, beta-in
THBS1 Thrombospondin 1
TNFAIP6 Tumor necrosis factor, alpha-induc
TNFSF11 Tumor necrosis factor (ligand) sup
P4HA3 Procollagen-proline, 2-oxoglutarate
(proline 4-hydroxylase), alpha poly
Intact>
damaged
BMPER BMP-binding endothelial regulator
CTSC Cathepsin C
C11orf8 Chromosome 11 open reading fram
The fold change and S.E.M. listed are the result of our microarray data. S
and for the method of calculating the fold change and the S.E.M. Public IDgene expression programs trigger differentiation and devel-
opment or alternatively apoptosis29. High temperature
requirement A (HtrA) and its homologues constitute the
HtrA family proteins, a group of heat shock-induced serine
proteases. HtrA proteins perform crucial functions with
regard to protein quality control in the periplasmic space,
functioning as both molecular chaperones and proteases30.
HtrA serine peptidase 3(HtrA3) bounds to various TGF-beta
proteins and inhibits the signaling of BMP-4, -2 and TGF-
beta 1. The inhibition occurs upstream of the cell surface
receptor. HtrA3 also shows proteolytic activities toward
beta-casein and some ECM proteoglycans. The protease
activity is absolutely required for the TGF-beta signal inhibi-
tion activity. The data suggest that HtrA3 has the overlap-
ping biological activities and the function in
complementary fashion in certain types of tissues31.
With regard to ECM, COL5A2, COL1A1, THBS1,
HAPLN1, P4HA3, FBLN1 and TNXB genes were found to
be differentially expressed between KBD and the normal
human cartilage. The developmental pattern of col5a2
expression closely resembles that of the type I collagen,
thus further substantiating the notion that these macromol-
ecules cooperate in the formation of ﬁbrillar networks in
abnormal-cartilaginous matrices in KBD32. These consisted
with the result of our study on abnormal chondrocyte differ-
entiation and abnormal expression of collagen types in
articular cartilage from patients with KBD10. Fibulins, and
particularly the splice variants of ﬁbulin-1 (FBLN1), play
a critical role in a number of developmental and pathological
processes. As an example, FBLN1 has been implicated in
limb malformations. It was reported that patients in a family
affected with a complex type of synpolydactyly have been
found to carry a balanced chromosomal translocation that
involves an alternatively spliced exon of FBLN1 33. A
human gene termed XB(TNXB) overlaps the P450c21B
gene encoding steroid 21-hydroxylase and encodes a pro-
tein that closely resembles ECM proteins34. Hyaluronan
and proteoglycan link protein 1 (HAPLN1), an ECM-linking
protein act as a stabilizers of the interaction between versi-
can and hyaluronan (HA) in various tissues35. Matrix
synthesis by articular chondrocytes is a critical factor inV
nd in data set obtained comparing intact vs damaged regions of OA
15
Public ID Fold
change
S.E.M.
) NM_015429 2.83 0.66
NM_000088 4.92 1.80
NM_000093 8.85 6.83
NM_003505 3.67 1.25
NM_007197 2.49 0.18
ne:
ltransferase-like 1
XM_031104 8.16 2.62
duced, 68 kDa NM_000358 7.86 3.44
NM_003246 2.95 0.76
ed protein 6 NM_007115 5.94 1.52
erfamily, member 11 NM_003701 8.53 8.01
4-dioxygenase
peptide III
NM_182904 3.42 1.40
precursor protein NM_133468 0.33 0.14
NM_001814 0.29 0.12
e 8 NM_001584 0.39 0.07
ee Materials and methods for the deﬁnition of the selection criteria
¼ accession number in public databases (RefSeq or GenBank).
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relationship between these genes and the apparent joint
deformity in KBD need to be investigated in future.
In previous studies, it was found that the levels of tumor
necrosis factor-alpha (TNF-alpha), VEGF and interleukin-
beta (IL-beta) in KBD group were higher than those in the
normal group36, and that chondrocyte apoptosis and differ-
ent expression of Bcl-2, Bax, Fas, and iNOS existed in ar-
ticular cartilage of KBD9. The contents of NO, iNOS and
sFas/APO-1 in sera of the adults with KBD were signiﬁ-
cantly higher than in normal one, suggesting that both
NO- and Fas-induced pathways may play a role in the path-
ogenesis in adult KBD37. With regard to chondrocyte prolif-
eration and apoptosis, TNFRSF11B, TNFSF11, TNFAIP6,
GAS2L1, BAK1, BCL2, CASP6, CASP8AP, PERP and
APAF1 genes were found differentially expressed in KBD
in this experiment. Programmed cell death is essential for
generation of the complex structural and functional organi-
sation of the cell. Most cells that undergoing programmed
cell death need genes that are essential for their death to
be transcriptionally activated. The product of TNF-stimu-
lated gene 6 (TSG-6), alternatively termed TNFAIP6 (for
TNF-alpha-induced protein 6), which speciﬁcally binds to
HA and to inter-alpha-inhibitor (I alpha I), shows potent
anti-inﬂammatory activity in acute and chronic inﬂammation,
notably in several models of autoimmune arthritis38.
Chondrocytes are a source of TSG-6 which may play
a role in cartilage remodeling and joint inﬂammation39.
That TSG-6 expression in KBD articular chondrocytes
possibly were implications in joint inﬂammation and carti-
lage degradation consisted with primal research40. The
GAS2 (growth-arrest-speciﬁc 2) gene, localized on human
chromosome 11p14.3ep1541 is a multifunctional gene in-
volved in the regulation of apoptosis and chondrogenesis42.
Expression of BCL2-antagonist/killer 1 (BAK1) was higher
in KBD samples43. BAK1 promotes cell death and counter-
acts the protection from apoptosis that is provided by B-cell
CLL/lymphoma (BCL2)44. Caspases (caspase 6, apoptosis-
related cysteine protease; CASP8AP, CASP8 associated
protein 2) are a growing family of cysteine proteases
involved with apoptosis. They are crucial for execution of
apoptosis, since inhibition of caspases by zVAD-fmk,
a broad spectrum caspase inhibitor, does not prevent
death, but results in necrosis rather than apoptosis45.
APAF1 (apoptosis signaling; death receptor signaling) acti-
vates procaspase-9 to caspase-9 initiating the apoptotic
pathway involving the downstream activation of caspases
3, 6, and 746. It has been reported that mitochondrial cyto-
chrome c functions as a cofactor with APAF-1 to activate
caspase-947. In addition, APAF-1 has been suggested as
an essential downstream effector of p53-mediated apoptotic
pathway after the DNA damage induced by radiation or
doxorubicin47. Besides the passive apoptosis pathway,
caspase-8 may directly induce the FaseFasL pathway or
be activated in a caspase-9-dependent manner48. The
PERP (p53 apoptosis effector) gene is a mediator of p53-
dependent apoptosis and is highly expressed in cells under-
going p53-dependent apoptosis49,50. These ﬁndings
suggest that apoptotic pathways and anti-apoptotic reac-
tions that participate in both repair and apoptosis induction
were present in chondrocytes necrosis with KBD.
The apparent joint impairment in adults will continue to de-
teriorate in older KBD patients due to the development of OA
as a result of joint deformity. We subsequently compared our
microarray result with the data of comparative analysis of
geneexpressionproﬁles in intact anddamaged regionsof hu-
man osteoarthritic cartilage. Fourteen genes, including ABIgene family, member 3 (NESH) binding protein (ABI3BP),
types I,V collagen, transforming growth factor, beta-induced
(TGFBI), TNF, alpha-induced protein 6 (TNFAIP6), TNF
(ligand) superfamily, member 11 (TNFSF11), and BMP-
binding endothelial regulator precursor protein (BMPER)
were found expressions in the same tendency. This suggests
that during the transition from normal cartilage to KBD
lesional cartilage, the gene expression proﬁle changes
before there is any apparent damage to the cartilage.
Because the expression levels of some genes probably
change during the transitional period from normal to normal
appearing cartilage, our study design might have allowed us
to miss some important genes that show no differences in
expression levels between normal and KBD cartilage. To
overcome this problem, further studies comparing intact
with damaged cartilage from same joints are needed.
Although we used rather high criteria to estimate a differ-
ential gene expression in KBD chondrocytes, and we could
conﬁrm many changes by parallel analyses, there are
several limitations of this experiment. Cartilages from the
same anatomical locations were collected from KBD
patients and the normal control tissues, and were used to
look at the difference on genetic expression. Thus, we
cannot completely exclude that some genetic effects might
be due to the different genetic background that were pres-
ent in the KBD and the normal groups. We also cannot
discriminate the difference between pathological tissue
and unaffected parts in the same arthrodial cartilage. Since
the microarray analysis is only a screening tool, and we
have learned that no one statistical algorithm is sufﬁcient
to derive an accurate view of the genes signiﬁcantly overex-
pressed or underexpressed in one population compared
with another, further studies are necessary to identify these
genes. Transgenic animal models can also be helpful to
conﬁrm the effect on these genetic changes.
In conclusion, a clear difference in the gene expression
proﬁle existed in KBD cartilage compared with normal
one. A group of genes appear to behave similarly in KBD
and OA cartilage, however, differential gene expression
speciﬁc for KBD was also observed. Their expressions
may imply a special mechanism responsible for the destruc-
tion of the articular cartilage in KBD. This also suggests that
the cartilage degeneration, apoptosis induction pathways
and matrix metabolism might be more important in KBD
cartilage. Elucidation of this mechanism is essential for
the development of effective treatments for KBD.Conﬂicts of interest
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